Allarity Therapeutics Inc (ALLR)

$1.97 +0.24 (13.87%)
Market Cap 28.80M
Revenue (ttm) 0.00
Net Income (ttm) -24.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.11
Volume 2,363,900
Avg Vol 8,792,053
Day's Range N/A - N/A
Shares Out 14.62M
Stochastic %K 74%
Beta 0.16
Analysts Sell
Price Target $9.00

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
24 School Street, 2nd Floor, Boston, United States
LifeisaMeme
LifeisaMeme Sep. 8 at 3:27 PM
$ALLR Did you make money in OCTO
1 · Reply
NoPetsonNewIssueDay
NoPetsonNewIssueDay Sep. 8 at 3:27 PM
$ALLR $5 soon. $OPEN $OCTO 🔥
1 · Reply
alteralgo
alteralgo Sep. 8 at 3:26 PM
$ALLR Profits from $OCTO coming in
1 · Reply
Hawkeye34X
Hawkeye34X Sep. 8 at 3:23 PM
$ALLR goodd
0 · Reply
TargasMum
TargasMum Sep. 8 at 3:20 PM
$ALLR
0 · Reply
Rich_Akin
Rich_Akin Sep. 8 at 3:16 PM
$ALLR $2 🙏🏻
1 · Reply
Phaarson
Phaarson Sep. 8 at 2:53 PM
$ALLR do like $OCTO
1 · Reply
Show_me_the_fkin_money
Show_me_the_fkin_money Sep. 8 at 2:36 PM
$OCTO Can We Pull One Of These?? $ALLR Imagine How Rich We Would Be 🤣🤣
1 · Reply
Popsiclestick
Popsiclestick Sep. 8 at 1:49 PM
$ALLR lets make $2 the floor!
0 · Reply
Nymn
Nymn Sep. 8 at 1:12 PM
$ALLR $5 gap fill + coming soon ( VERY SOON ) to a theatre near you! 👍🚀
0 · Reply
Latest News on ALLR
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 26, 2025, 8:00 AM EDT - 13 days ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Aug 15, 2025, 4:30 PM EDT - 23 days ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Jul 15, 2025, 8:00 AM EDT - 7 weeks ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Jul 7, 2025, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 27, 2025, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 3 months ago

Allarity Therapeutics Announces Changes to Board of Directors

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

May 9, 2025, 4:05 PM EDT - 4 months ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Apr 14, 2025, 9:04 AM EDT - 5 months ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Mar 14, 2025, 4:30 AM EDT - 6 months ago

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 13, 2025, 8:30 AM EDT - 6 months ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Mar 6, 2025, 8:00 AM EST - 6 months ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 24, 2025, 8:00 AM EST - 7 months ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 14, 2025, 10:00 AM EST - 7 months ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Shareholders to Inquire about Securities Investigation

Feb 13, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect

Feb 12, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out

Feb 11, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation

Feb 10, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation

Feb 9, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 7, 2025, 10:00 AM EST - 7 months ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect

Feb 6, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 6, 2025, 8:00 AM EST - 7 months ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Feb 4, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out

Feb 3, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Feb 2, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Jan 31, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Jan 30, 2025, 8:00 AM EST - 7 months ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 8 months ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 18, 2024, 8:00 AM EST - 10 months ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 11, 2024, 3:45 PM EST - 10 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Nov 11, 2024, 11:15 AM EST - 10 months ago

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Nov 9, 2024, 12:30 PM EST - 10 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 8, 2024, 7:00 PM EST - 10 months ago

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 8, 2024, 9:45 AM EST - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Nov 7, 2024, 11:00 AM EST - 10 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

Nov 6, 2024, 11:00 AM EST - 10 months ago

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 10 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 11 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud

Oct 29, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 27, 2024, 11:00 AM EDT - 11 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

LifeisaMeme
LifeisaMeme Sep. 8 at 3:27 PM
$ALLR Did you make money in OCTO
1 · Reply
NoPetsonNewIssueDay
NoPetsonNewIssueDay Sep. 8 at 3:27 PM
$ALLR $5 soon. $OPEN $OCTO 🔥
1 · Reply
alteralgo
alteralgo Sep. 8 at 3:26 PM
$ALLR Profits from $OCTO coming in
1 · Reply
Hawkeye34X
Hawkeye34X Sep. 8 at 3:23 PM
$ALLR goodd
0 · Reply
TargasMum
TargasMum Sep. 8 at 3:20 PM
$ALLR
0 · Reply
Rich_Akin
Rich_Akin Sep. 8 at 3:16 PM
$ALLR $2 🙏🏻
1 · Reply
Phaarson
Phaarson Sep. 8 at 2:53 PM
$ALLR do like $OCTO
1 · Reply
Show_me_the_fkin_money
Show_me_the_fkin_money Sep. 8 at 2:36 PM
$OCTO Can We Pull One Of These?? $ALLR Imagine How Rich We Would Be 🤣🤣
1 · Reply
Popsiclestick
Popsiclestick Sep. 8 at 1:49 PM
$ALLR lets make $2 the floor!
0 · Reply
Nymn
Nymn Sep. 8 at 1:12 PM
$ALLR $5 gap fill + coming soon ( VERY SOON ) to a theatre near you! 👍🚀
0 · Reply
stocksbuytrade
stocksbuytrade Sep. 8 at 12:38 PM
$ALLR 🤑
0 · Reply
Show_me_the_fkin_money
Show_me_the_fkin_money Sep. 8 at 12:34 PM
$ALLR LOL 💤
0 · Reply
Jibbajew
Jibbajew Sep. 8 at 12:25 PM
$ALLR 🚀🧨
0 · Reply
MissFred
MissFred Sep. 8 at 11:56 AM
$AREB $OPEN $UBER $ALLR
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 11:43 AM
$ALLR Excellent article that nails exactly where ALLR stands right now. So if you want to update your ALLR knowledge or get acquainted with ALLR, this is a must read. https://beyondspx.com/quote/ALLR/analysis/allarity-therapeutics-unlocking-precision-oncology-with-drp-and-stenoparib-s-accelerated-path-nasdaq-allr
0 · Reply
gms888777777
gms888777777 Sep. 8 at 11:18 AM
$ALLR
0 · Reply
gms888777777
gms888777777 Sep. 8 at 10:51 AM
$ALLR no news going down...
0 · Reply
NoPetsonNewIssueDay
NoPetsonNewIssueDay Sep. 8 at 1:25 AM
$ALLR exciting weeks ahead for this one! Any additional updates from the company could send this over $5 quickly!
0 · Reply
GSP
GSP Sep. 7 at 11:27 PM
I like the way $ALLR has recovered from this gap up reversal candle a couple of weeks ago. .
2 · Reply
GSP
GSP Sep. 7 at 4:41 PM
$FDMT $BLNE $PTNM $ALLR $MOVE
0 · Reply
Jibbajew
Jibbajew Sep. 7 at 3:39 PM
$ALLR $KSS $OPEN
0 · Reply
Nymn
Nymn Sep. 7 at 2:58 PM
$ALLR wonder if the bought back shares will be used to award insiders… They would definitely bank seeing how cheaply those were acquired. I believe they were asking for 3 mil shares or something? Talk about cashing in! 🚀👍😎
0 · Reply